Skip to main content
Fig. 7 | Cardiovascular Diabetology

Fig. 7

From: The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

Fig. 7

Transcriptional modulation by empagliflozin on genes related to fatty acid metabolism (PPARα and ACADM) and natriuretic peptides (NPPA and NPPB), and TNF-α. The transcriptional expression of genes in the atrial tissue (a–e) and in the ventricular tissue (f–j) of control rats (WKY), spontaneous hypertensive rats (SHR), and empagliflozin-treated SHR (EMPA) (n = 4 for each group). Statistical significance is labeled as *for SHR vs WKY; #for EMPA vs SHR; $for EMPA vs WKY

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840